Bod Australia has reported promising results from a proof-of-concept study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract.
The trial forms the basis for the launch of a new medicinal cannabis product to be sold under Bod’s existing MediCabilis brand as MediCabilis CBG 50.
Available from next month, Bod claimed it would be the first pharmaceutical-grade CBG product to launch in the Australian and UK prescription markets.
The three-month study investigated the safety and efficacy of CBG on symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety.
Some 74% of trial participants reported a noticeable improvement in their condition within two-to-four weeks of using MediCabilis CBG 50.
Bod will use the data in its ongoing outreach work with doctors and approved prescribers in Australia and the UK.
CEO Jo Patterson said: “The completion of this initiative has highlighted that MediCabilis CBG 50 is both safe and effective for use across a range of new symptoms that our product has not been previously prescribed for.
“The study will also allow Bod to explore the possibility of using its extract as an alternative treatment or all-encompassing route for conditions that require a mix of surgery, medication and other routines.”
